Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-26T03:29:12.390Z Has data issue: false hasContentIssue false

Chapter 11 - Novel Biological Treatment Strategies

from Section 3 - Novel Treatment Strategies

Published online by Cambridge University Press:  08 August 2019

By
G. Paul Amminger  and
Maximus Berger
Edited by
Patrick D. McGorry  and
Ian B. Hickie
Patrick D. McGorry
Affiliation:
University of Melbourne
Ian B. Hickie
Affiliation:
University of Sydney
Get access

Summary

The identification of people at high risk for future mental disorders is accompanied by the imperative to provide stage-adequate treatments that successfully prevent progression to more severe illness stages. Current evidence-based treatments include psychological and psychosocial treatments on one hand as well as pharmacotherapy. The latter is limited by inadequate efficacy and prominent side effects in many cases, making the discovery of novel biological treatment strategies necessary. Such novel treatments need to be safe, effective, characterised by a benign side effect profile and accessible to young people. In this chapter, emerging biological treatment approaches are reviewed and discussed in regard to their potential impact on early intervention and clinical staging. Substances reviewed here include long-chain omega-3 fatty acids (fish oil), n-acetylcysteine (NAC), cannabidiol and repeated transcranial magnetic stimulation (rTMS) with a particular focus on recent advancements in their application in youth with incipient mental disorders. Finally, research priorities in the field of treatment trials are discussed in this chapter.

Keywords

clinical stagingbiotherapyomega-3 fatty acidsN-acetylcysteinetranscranial magnetic stimulationtranscranial magnetic stimulationmental disorders
Type
Chapter
Information
Clinical Staging in Psychiatry
Making Diagnosis Work for Research and Treatment
 , pp. 221 - 240
Publisher: Cambridge University Press
Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Amminger, G. P., Berger, M., Rice, S. M., Davey, C. G., Schäfer, M. R., & McGorry, P. D. (2017). Novel biotherapies are needed in youth mental health. Australasian Psychiatry, 25(2), 117–120.Google Scholar
Amminger, G. P., Chanen, A. M., Ohmann, S., Klier, C. M., Mossaheb, N., Bechdolf, A., … Schäfer, M. R. (2013). Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial. Canadian Journal of Psychiatry, 58(7), 402–408.Google Scholar
Amminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, M, … Berger, G. E. (2010). Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Archives of General Psychiatry, 67(2), 146–154.CrossRefGoogle ScholarPubMed
Amminger, G. P., Schäfer, M. R., Schlögelhofer, M., Klier, C. M., & McGorry, P. D. (2015). Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nature Communications, 6, 7934.Google Scholar
Arakawa, M., & Ito, Y. (2007). N-acetylcysteine and neurodegenerative diseases: basic and clinical pharmacology. Cerebellum, 6(4), 308–314.Google Scholar
Arseneault, L., Cannon, M., Witton, J., & Murray, R. M. (2004). Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry, 184, 110–117.Google Scholar
Assies, J., Pouwer, F., Lok, A., Mocking, R. J. T., Bockting, C. L. H., Visser, I., … Schene, A. H. (2010). Plasma and erythrocyte fatty acid patterns in patients with recurrent depression: a matched case-control study. PLoS One, 5(5), e10635.Google Scholar
Berg, D., Youdim, M. B. H., & Riederer, P. (2004). Redox imbalance. Cell and Tissue Research, 318(1), 201–213.Google Scholar
Berg, K. A., Maayani, S., & Clarke, W. P. (1996). 5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism. Molecular Pharmacology, 50(4), 1017–1023.Google Scholar
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., De Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., … Crippa, J. A. S. (2011a). Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology, 36(6), 1219–1226.Google Scholar
Bergamaschi, M. M., Queiroz, R. H. C., Zuardi, A. W., & Crippa, J. A. S. (2011b). Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current Drug Safety, 6(4), 237–249.Google Scholar
Berger, M., Smesny, S., Kim, S., Davey, C., Rice, S., Sarnyai, Z., … McGorry, P. (2017). Omega-6 to omega-3 polyunsaturated fatty acid ratio and subsequent mood disorders in young people with at-risk mental states: a 7-year longitudinal study. Translational Psychiatry, 7(8), e1220.Google Scholar
Berk, M., Copolov, D., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., … Bush, A. I. (2008). N-acetyl cysteine as a glutathione precursor for schizophrenia: a double-blind, randomized, placebo-controlled trial. Biological Psychiatry, 64(5), 361–368.Google Scholar
Berk, M., Malhi, G. S., Gray, L. J., & Dean, O. M. (2013a). The promise of N-acetylcysteine in neuropsychiatry. Trends in Pharmacological Sciences, 34(3), 167–177.Google Scholar
Berk, M., Williams, L. J., Jacka, F. N., O’Neil, A., Pasco, J. A., Moylan, S., … Maes, M. (2013b). So depression is an inflammatory disease, but where does the inflammation come from? BMC Medicine, 11, 200.Google Scholar
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics, 12(4), 825–836.Google Scholar
Bloch, M. H., & Hannestad, J. (2012). Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Molecular Psychiatry, 17(12), 1272–1282.Google Scholar
Bloch, Y., Grisaru, N., Harel, E. V., Beitler, G., Faivel, N., Ratzoni, G., … Levkovitz, Y. (2008). Repetitive transcranial magnetic stimulation in the treatment of depression in adolescents: an open-label study. Journal of ECT, 24(2), 156–159.Google Scholar
Blondeau, N., Nguemeni, C., Debruyne, D. N., Piens, M., Wu, X., Pan, H., … Heurteaux, C. (2009). Subchronic alpha-linolenic acid treatment enhances brain plasticity and exerts an antidepressant effect: a versatile potential therapy for stroke. Neuro-Psychopharmacology, 34(12), 2548–2559.Google Scholar
Bossong, M. G., Jager, G., Bhattacharyya, S., & Allen, P. (2014a). Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies. Current Pharmaceutical Design, 20(13), 2114–2125.Google Scholar
Bossong, M. G., Jansma, J. M., Bhattacharyya, S., & Ramsey, N. F. (2014b). Role of the endocannabinoid system in brain functions relevant for schizophrenia: an overview of human challenge studies with cannabis or Δ9-tetrahydrocannabinol (THC). Progress in Neuropsychopharmacology and Biological Psychiatry, 52, 53–69.Google Scholar
Brunoni, A. R., Chaimani, A., Moffa, A. H., Razza, L. B., Gattaz, W. F., Daskalakis, Z. J., & Carvalho, A. F. (2017). Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: a systematic review with network meta-analysis. JAMA Psychiatry, 74(2), 143–152.CrossRefGoogle ScholarPubMed
Ceccarini, J., De Hert, M., Van Winkel, R., Peuskens, J., Bormans, G., Kranaster, L., … Van Laere, K. (2013). Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. NeuroImage, 79, 304–312.Google Scholar
Chalon, S., Vancassel, S., Zimmer, L., Guilloteau, D., & Durand, G. (2001). Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids, 36(9), 937–944.Google Scholar
Compton, M. T. (2010). Fish oil to fend off psychosis: new evidence. Medscape.Google Scholar
Croarkin, P. E., Nakonezny, P. A., Wall, C. A., Murphy, L. L., Sampson, S. M., Frye, M. A., & Port, J. D. (2016). Transcranial magnetic stimulation potentiates glutamatergic neurotransmission in depressed adolescents. Psychiatry Research: Neuroimaging, 247, 25–33.Google Scholar
Croarkin, P. E., Wall, C. A., Nakonezny, P. A., Buyukdura, J. S., Husain, M. M., Sampson, S. M., … Kozel, F. A. (2012). Increased cortical excitability with prefrontal high-frequency repetitive transcranial magnetic stimulation in adolescents with treatment-resistant major depressive disorder. Journal of Child and Adolescent Psychopharmacology, 22(1), 56–64.Google Scholar
Das, R. K., Kamboj, S. K., Ramadas, M., Yogan, K., Gupta, V., Redman, E., … Morgan, C. J. A. (2013). Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology, 226(4), 781–792.CrossRefGoogle ScholarPubMed
Dean, O., Giorlando, F., & Berk, M. (2011). N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. Journal of Psychiatry and Neuroscience, 36(2), 78–86.CrossRefGoogle ScholarPubMed
Delion, S., Chalon, S., Herault, J., Guilloteau, D., Besnard, J. C., & Durand, G. (1994). Chronic dietary α-linolenic acid deficiency alters dopaminergic and serotoninergic neurotransmission in rats. Journal of Nutrition, 124(12), 2466–2476.CrossRefGoogle ScholarPubMed
Desfossés, J., Stip, E., Bentaleb, L. A., & Potvin, S. (2010). Endocannabinoids and schizophrenia. Pharmaceuticals, 3(10), 3101–3126.Google Scholar
Do, K. Q., Trabesinger, A. H., Kirsten-Krüger, M., Lauer, C. J., Dydak, U., Hell, D., … Cuénod, M. (2000). Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. European Journal of Neuroscience, 12(10), 3721–3728.Google Scholar
Dodd, S., Dean, O., Copolov, D. L., Malhi, G. S., & Berk, M. (2008). N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opinion on Biological Therapy, 8(12), 1955–1962.Google Scholar
Dringen, R. (2000). Metabolism and functions of glutathione in brain. Progress in Neurobiology, 62(6), 649–671.Google Scholar
Flatow, J., Buckley, P., & Miller, B. J. (2013). Meta-analysis of oxidative stress in schizophrenia. Biological Psychiatry, 74(6), 400–409.CrossRefGoogle ScholarPubMed
Foti, D. J., Kotov, R., Guey, L. T., & Bromet, E. J. (2010). Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. American Journal of Psychiatry, 167(8), 987–993.CrossRefGoogle ScholarPubMed
Freeman, M. P., Hibbeln, J. R., Wisner, K. L., Davis, J. M., Mischoulon, D., Peet, M., … Stoll, A. L. (2006). Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Journal of Clinical Psychiatry, 67(12), 1954–1967.Google Scholar
Garland, M. R., & Hallahan, B. (2006). Essential fatty acids and their role in conditions characterised by impulsivity. International Review of Psychiatry, 18(2), 99–105.Google Scholar
Garland, M. R., Hallahan, B., McNamara, M., Carney, P. A., Grimes, H., Hibbeln, J. R., … Conroy, R. M. (2007). Lipids and essential fatty acids in patients presenting with self-harm. British Journal of Psychiatry, 190, 112–117.Google Scholar
Gaynes, B. N., Lloyd, S. W., Lux, L., Gartlehner, G., Hansen, R. A., Brode, S., … Lohr, K. N. (2014). Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. Journal of Clinical Psychiatry, 75(5), 477–489.Google Scholar
George, M. S., Wassermann, E. M., Williams, W. A., Callahan, A., Ketter, T. A., Basser, P., … Post, R. M. (1995). Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. NeuroReport, 6(14), 1853–1856.Google Scholar
Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., … Piomelli, D. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology, 29(11), 2108–2114.CrossRefGoogle ScholarPubMed
Hallahan, B., & Garland, M. R. (2005). Essential fatty acids and mental health. British Journal of Psychiatry, 186, 275–277.CrossRefGoogle ScholarPubMed
Hallahan, B., Ryan, T., Hibbeln, J. R., Murray, I. T., Glynn, S., Ramsden, C. E., … Davis, J. M. (2016). Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. British Journal of Psychiatry, 209(3), 192–201.Google Scholar
Hedelin, M., Löf, M., Olsson, M., Lewander, T., Nilsson, B., Hultman, C. M., & Weiderpass, E. (2010). Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33 000 women from the general population. BMC Psychiatry, 10, 38.Google Scholar
Hibbeln, J. R. (1998). Fish consumption and major depression. Lancet, 351(9110), 1213.Google Scholar
Hibbeln, J. R., & Salem, N. Jr (1995). Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. American Journal of Clinical Nutrition, 62(1), 1–9.Google Scholar
Hillard, C. J., & Liu, Q. S. (2014). Endocannabinoid signaling in the etiology and treatment of major depressive illness. Current Pharmaceutical Design, 20(23), 3795–3811.Google Scholar
Horrobin, D. F. (1998). The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Research, 30(3), 193–208.Google Scholar
Hu, S., Wang, S., Zhang, M., Wang, J., Hu, J., Huang, M., … Xu, W. (2011). Repetitive transcranial magnetic stimulation-induced seizure of a patient with adolescent-onset depression: a case report and literature review. Journal of International Medical Research, 39(5), 2039–2044.Google Scholar
Iseger, T. A., & Bossong, M. G. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research, 162(1–3), 153–161.Google Scholar
James, M. J., Sullivan, T. R., Metcalf, R. G., & Cleland, L. G. (2014). Pitfalls in the use of randomised controlled trials for fish oil studies with cardiac patients. British Journal of Nutrition, 112(5), 812–820.Google Scholar
Kano, M., Ohno-Shosaku, T., Hashimotodani, Y., Uchigashima, M., & Watanabe, M. (2009). Endocannabinoid-mediated control of synaptic transmission. Physiological Reviews, 89(1), 309–380.Google Scholar
Keshavan, M. S., Sanders, R. D., Pettegrew, J. W., Dombrowsky, S. M., & Panchalingam, K. S. (1993). Frontal lobe metabolism and cerebral morphology in schizophrenia: 31P MRS and MRI studies. Schizophrenia Research, 10(3), 241–246.Google Scholar
Kiecolt-Glaser, J. K., Epel, E. S., Belury, M. A., Andridge, R., Lin, J., Glaser, R., … Blackburn, E. (2013). Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: a randomized controlled trial. Brain, Behavior, and Immunity, 28, 16–24.Google Scholar
Kim, S. W., Jhon, M., Kim, J. M., Smesny, S., Rice, S., Berk, M., … Amminger, G. P. (2016). Relationship between erythrocyte fatty acid composition and psychopathology in the Vienna omega-3 study. PLoS One, 11(3), e0151417.Google Scholar
Kraemer, H. C. (2016). Messages for clinicians: moderators and mediators of treatment outcome in randomized clinical trials. American Journal of Psychiatry, 173(7), 672–679.CrossRefGoogle ScholarPubMed
Lavoie, S., Berger, M., Schlögelhofer, M., Schäfer, M. R., Rice, S., Kim, S. W., … Amminger, G. P. (2017). Erythrocyte glutathione levels as long-term predictor of transition to psychosis. Translational Psychiatry, 7(3), e1064.CrossRefGoogle ScholarPubMed
Leichsenring, F., Leibing, E., Kruse, J., New, A. S., & Leweke, F. (2011). Borderline personality disorder. Lancet, 377(9759), 74–84.Google Scholar
Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999). Elevated endogenous cannabinoids in schizophrenia. NeuroReport, 10(8), 1665–1669.Google Scholar
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., … Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2, e94.Google Scholar
Lewis, M. D., Hibbeln, J. R., Johnson, J. E., Lin, Y. H., Hyun, D. Y., & Loewke, J. D. (2011). Suicide deaths of active-duty US military and omega-3 fatty-acid status: a case-control comparison. Journal of Clinical Psychiatry, 72(12), 1585–1590.Google Scholar
Libov, I., Miodownik, C., Bersudsky, Y., Dwolatzky, T., & Lerner, V. (2007). Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. Journal of Clinical Psychiatry, 68(7), 1031–1037.Google Scholar
Lin, P. Y., Chang, C. H., Chong, M. F. F., Chen, H., & Su, K. P. (2017). Polyunsaturated fatty acids in perinatal depression: a systematic review and meta-analysis. Biological Psychiatry, 82(8), 560–569.Google Scholar
Loo, C., McFarquhar, T., & Walter, G. (2006). Transcranial magnetic stimulation in adolescent depression. Australasian Psychiatry, 14(1), 81–85.Google Scholar
Lutz, B., Marsicano, G., Maldonado, R., & Hillard, C. J. (2015). The endocannabinoid system in guarding against fear, anxiety and stress. Nature Reviews Neuroscience, 16(12), 705–718.Google Scholar
Magavi, L. R., Reti, I. M., & Vasa, R. A. (2017). A review of repetitive transcranial magnetic stimulation for adolescents with treatment-resistant depression. International Review of Psychiatry, 29(2), 79–88.Google Scholar
Mayer, G., Aviram, S., Walter, G., Levkovitz, Y., & Bloch, Y. (2012). Long-term follow-up of adolescents with resistant depression treated with repetitive transcranial magnetic stimulation. Journal of ECT, 28(2), 84–86.Google Scholar
McGorry, P. D., Hickie, I. B., Yung, A. R., Pantelis, C., & Jackson, H. J. (2006). Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Australian and New Zealand Journal of Psychiatry, 40(8), 616–622.Google Scholar
McGorry, P. D., Nelson, B., Markulev, C., Yuen, H. P., Schäfer, M. R., Mossaheb, N., … Amminger, G. P. (2017). Effect of ω-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiatry, 74(1), 19–27.Google Scholar
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet, 370(9584), 319–328.Google Scholar
Mossaheb, N., Schloegelhofer, M., Schaefer, M. R., Fusar-Poli, P., Smesny, S., McGorry, P., … Amminger, G. P. (2012). Polyunsaturated fatty acids in emerging psychosis. Current Pharmaceutical Design, 18(4), 576–591.Google Scholar
Noaghiul, S., & Hibbeln, J. R. (2003). Cross-national comparisons of seafood consumption and rates of bipolar disorders. American Journal of Psychiatry, 160(12), 2222–2227.Google Scholar
Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews, 58(3), 389–462.Google Scholar
Palta, P., Samuel, L. J., Miller, E. R., & Szanton, S. L. (2014). Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosomatic Medicine, 76(1), 12–19.Google Scholar
Parker, G., Gibson, N. A., Brotchie, H., Heruc, G., Rees, A. M., & Hadzi-Pavlovic, D. (2006). Omega-3 fatty acids and mood disorders. American Journal of Psychiatry, 163(6), 969–978.Google Scholar
Pathak, V., Sinha, V. K., & Praharaj, S. K. (2015). Efficacy of adjunctive high frequency repetitive transcranial magnetic stimulation of right prefrontal cortex in adolescent mania: a randomized sham-controlled study. Clinical Psychopharmacology and Neuroscience, 13(3), 245–249.Google Scholar
Piomelli, D., Astarita, G., & Rapaka, R. (2007). A neuroscientist’s guide to lipidomics. Nature Reviews Neuroscience, 8(10), 743–754.Google Scholar
Prud’Homme, M., Cata, R., & Jutras-Aswad, D. (2015). Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Substance Abuse, 9, 33–38.Google Scholar
Rais, M., Cahn, W., Van Haren, N., Schnack, H., Caspers, E., Pol, H. H., & Kahn, R. (2008). Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. American Journal of Psychiatry, 165(4), 490–496.Google Scholar
Rapaport, M. H., Nierenberg, A. A., Schettler, P. J., Kinkead, B., Cardoos, A., Walker, R., & Mischoulon, D. (2016). Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Molecular Psychiatry, 21(1), 71–79.Google Scholar
Rice, S. M., Hickie, I. B., Yung, A. R., Mackinnon, A., Berk, M., Davey, C., … Amminger, G. P. (2016). Youth depression alleviation: the Fish Oil Youth Depression Study (YoDA-F) – a randomized, double-blind, placebo-controlled treatment trial. Early Intervention in Psychiatry, 10(4), 290–299.Google Scholar
Rice, S. M., Schäfer, M. R., Klier, C., Mossaheb, N., Vijayakumar, N., & Amminger, G. P. (2015). Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controls. Psychiatry Research, 228(1), 174–176.Google Scholar
Ripoll, L. H. (2013). Psychopharmacologic treatment of borderline personality disorder. Dialogues in Clinical Neuroscience, 15(2), 213–224.Google Scholar
Rougemont, M., Do, K. Q., & Castagné, V. (2002). New model of glutathione deficit during development: effect on lipid peroxidation in the rat brain. Journal of Neuroscience Research, 70(6), 774–783.Google Scholar
Sánchez-Villegas, A., Delgado-Rodríguez, M., Alonso, A., Schlatter, J., Lahortiga, F., Serra-Majem, L., & Martínez-González, M. A. (2009). Association of the Mediterranean dietary pattern with the incidence of depression: the Seguimiento Universidad de Navarra/University of Navarra follow-up (SUN) cohort. Archives of General Psychiatry, 66(10), 1090–1098.Google Scholar
Saunders, E. F. H., Ramsden, C. E., Sherazy, M. S., Gelenberg, A. J., Davis, J. M., & Rapoport, S. I. (2016). Omega-3 and omega-6 polyunsaturated fatty acids in bipolar disorder: a review of biomarker and treatment studies. Journal of Clinical Psychiatry, 77(10), e1301–e1308.Google Scholar
Schulz, T. J., Zarse, K., Voigt, A., Urban, N., Birringer, M., & Ristow, M. (2007). Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metabolism, 6(4), 280–293.Google Scholar
Scott, J., Leboyer, M., Hickie, I., Berk, M., Kapczinski, F., Frank, E., … McGorry, P. (2013). Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value. British Journal of Psychiatry, 202(4), 243–245.Google Scholar
Segal, A. W. (2005). How neutrophils kill microbes. Annual Review of Immunology, 23, 197–223.Google Scholar
Serhan, C. N. (2014). Pro-resolving lipid mediators are leads for resolution physiology. Nature, 510(7503), 92–101.Google Scholar
Serhan, C. N., & Petasis, N. A. (2011). Resolvins and protectins in inflammation resolution. Chemical Reviews, 111(10), 5922–5943.Google Scholar
Shamir, E., Barak, Y., Shalman, I., Laudon, M., Zisapel, N., Tarrasch, R., … Weizman, R. (2001). Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Archives of General Psychiatry, 58(11), 1049–1052.Google Scholar
Simopoulos, A. P. (2011). Evolutionary aspects of diet: the omega-6/omega-3 ratio and the brain. Molecular Neurobiology, 44(2), 203–215.Google Scholar
Sommer, I. E., van Westrhenen, R., Begemann, M. J., de Witte, L. D., Leucht, S., & Kahn, R. S. (2013). Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophrenia Bulletin, 40(1), 181–191.Google Scholar
Su, K.-P., Matsuoka, Y., & Pae, C.-U. (2015). Omega-3 polyunsaturated fatty acids in prevention of mood and anxiety disorders. Clinical Psychopharmacology and Neuroscience, 13(2), 129–137.CrossRefGoogle ScholarPubMed
Sublette, M. E., Ellis, S. P., Geant, A. L., & Mann, J. J. (2011). Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. Journal of Clinical Psychiatry, 72(12), 1577–1584.Google Scholar
Sublette, M. E., Galfalvy, H. C., Hibbeln, J. R., Keilp, J. G., Malone, K. M., Oquendo, M. A., & Mann, J. J. (2014). Polyunsaturated fatty acid associations with dopaminergic indices in major depressive disorder. International Journal of Neuropsychopharmacology, 17(3), 383–391.Google Scholar
Sublette, M. E., Russ, M. J., & Smith, G. S. (2004). Evidence for a role of the arachidonic acid cascade in affective disorders: a review. Bipolar Disorders, 6(2), 95–105.Google Scholar
Tanskanen, A., Hibbeln, J. R., Hintikka, J., Haatainen, K., Honkalampi, K., & Viinamäki, H. (2001). Fish consumption, depression, and suicidality in a general population. Archives of General Psychiatry, 58(5), 512–513.CrossRefGoogle ScholarPubMed
Teng, S., Guo, Z., Peng, H., Xing, G., Chen, H., He, B., … Mu, Q. (2017). High-frequency repetitive transcranial magnetic stimulation over the left DLPFC for major depression: session-dependent efficacy: a meta-analysis. European Psychiatry, 41, 75–84.Google Scholar
Twenge, J. M., Gentile, B., DeWall, C. N., Ma, D., Lacefield, K., & Schurtz, D. R. (2010). Birth cohort increases in psychopathology among young Americans, 1938–2007: a cross-temporal meta-analysis of the MMPI. Clinical Psychology Review, 30(2), 145–154.Google Scholar
Veen, N. D., Selten, J.-P., van der Tweel, I., Feller, W. G., Hoek, H. W., & Kahn, R. S. (2004). Cannabis use and age at onset of schizophrenia. American Journal of Psychiatry, 161(3), 501–506.Google Scholar
Venna, V. R., Deplanque, D., Allet, C., Belarbi, K., Hamdane, M., & Bordet, R. (2009). PUFA induce antidepressant-like effects in parallel to structural and molecular changes in the hippocampus. Psychoneuroendocrinology, 34(2), 199–211.Google Scholar
von Schacky, C. (2009). Cardiovascular disease prevention and treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids, 81(2–3), 193–198.Google Scholar
Wall, C. A., Croarkin, P. E., Maroney-Smith, M. J., Haugen, L. M., Baruth, J. M., Frye, M. A., … Port, J. D. (2016). Magnetic resonance imaging-guided, open-label, high-frequency repetitive transcranial magnetic stimulation for adolescents with major depressive disorder. Journal of Child and Adolescent Psychopharmacology, 26(7), 582–589.Google Scholar
Wall, C. A., Croarkin, P. E., Sim, L. A., Husain, M. M., Janicak, P. G., Kozel, F. A., … Sampson, S. M. (2011). Adjunctive use of repetitive transcranial magnetic stimulation in depressed adolescents: a prospective, open pilot study. Journal of Clinical Psychiatry, 72(9), 1263–1269.Google Scholar
Wong, D. F., Kuwabara, H., Horti, A. G., Raymont, V., Brasic, J., Guevara, M., … Nandi, A. (2010). Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C] OMAR. NeuroImage, 52(4), 1505–1513.CrossRefGoogle ScholarPubMed
Yao, J. K., & Keshavan, M. S. (2011). Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view. Antioxidants & Redox Signaling, 15(7), 2011–2035.Google Scholar
Zanettini, C., Panlilio, L. V., Aliczki, M., Goldberg, S. R., Haller, J., & Yasar, S. (2011). Effects of endocannabinoid system modulation on cognitive and emotional behavior. Frontiers in Behavioral Neuroscience, 5, 57.CrossRefGoogle ScholarPubMed
Zhang, X. Y., Zhou, D. F., Cao, L. Y., Xu, C. Q., & Wu, G. Y. (2004). The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. Journal of Clinical Psychopharmacology, 24(1), 83–86.Google Scholar
Zuardi, A. W., Hallak, J. E., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. S. (2006). Cannabidiol monotherapy for treatment-resistant schizophrenia. Journal of Psychopharmacology, 20(5), 683–686.Google Scholar
Zuardi, A. W., Morais, S., Guimaraes, F., & Mechoulam, R. (1995). Antipsychotic effect of cannabidiol. Journal of Clinical Psychiatry, 56(10), 485–486.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×